

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * GENERAL ELECTRIC CO			2. Issuer Name and Ticker or Trading Symbol NEOGENOMICS INC [NEO]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)		
(Last) (First) (Middle) 41 FARNSWORTH STREET			3. Date of Earliest Transaction (Month/Day/Year) 06/25/2018					
(Street) BOSTON, MA 02210			4. If Amendment, Date Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		
(City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned					
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)	Price	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)



Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Series A Convertible Preferred Stock	\$ 7.5	06/25/2018		(1)	6,864,000	(2)	12/30/2025	Common Stock	(3)	\$ 7.3 (4)	0	I (5)	See Footnote (5)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
GENERAL ELECTRIC CO 41 FARNSWORTH STREET BOSTON, MA 02210		X		
GE Medical Systems Information Technologies, Inc. 8200 WEST TOWER AVENUE MILWAUKEE, WI 53223		X		

Signatures

By: /s/ Raul Grable, Attorney-in-Fact for General Electric Company		06/26/2018
 Signature of Reporting Person		Date
By: /s/ Raul Grable, Attorney-in-Fact for GE Medical Systems Information Technologies, Inc.		06/26/2018
 Signature of Reporting Person		Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) This Form 4 is being filed in connection with the redemption by NeoGenomics, Inc. ("Issuer") of all of Issuer's outstanding shares of Series A convertible preferred stock, par value \$0.001 per share ("Preferred Stock").
- (2) The shares of Preferred Stock were exercisable at any time after December 30, 2018, to the extent that the volume weighted average price of Issuer's common stock equaled or exceeded \$8.00 per share, as adjusted for standard anti-dilution adjustments, for 30 consecutive trading days.
- (3) Based on the conversion price and the liquidation preference of the Preferred Stock in effect on the date of this filing, 6,997,467 shares of common stock could have been issued had the Preferred Stock been converted in full on the date of this filing.
- (4) The \$7.30 per share redemption price was less than the original stated value of \$7.50 per share of Preferred Stock.
- GE Medical Systems Information Technologies, Inc. ("GE InfoTech") is a wholly owned subsidiary of General Electric Company, a New York corporation ("General Electric"). General

(5) Electric disclaims beneficial ownership of the securities held by GE InfoTech except to the extent of its pecuniary interest, and the filing of this Form shall not be deemed an admission that General Electric is the beneficial owner of any equity securities of Issuer for purposes of Section 16 or any other purpose.

Remarks:

Exhibit List:

Exhibit 24.1 - Power of Attorney (General Electric Company)

Exhibit 24.2 - Power of Attorney (GE Medical Systems Information Technologies, Inc.)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY

Effective as of June 22, 2018 (the "Effective Date"), GENERAL ELECTRIC COMPANY (the "Company"), a corporation organized and existing under and by virtue of the laws of the State of New York, United States of America, and having a principal place of business at 41 Farnsworth Street, Boston, MA 02210, United States of America, hereby appoints and constitutes the following persons:

Name of Attorney:

Emmanuel Ligner	Stephen Kanovsky
Raul Grable	Derek Vander Heide

each individually as its true and lawful attorney-in-fact (each, an "Attorney-in-Fact"), hereby giving and granting him or her full power and authority in the name and on behalf of the Company to do the following:

Each Attorney shall have the power and authority to execute and deliver any Schedule 13D, Schedule 13G or Forms 3, 4 and 5 or any amendments thereto required to be filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934 on behalf of the Company with regard to any securities owned by the Company or any of its subsidiaries; and, in connection with the foregoing, to execute and deliver all documents, acknowledgments, consents and other agreements and to take such further action as may be necessary or convenient for the Company in order to more effectively carry out the intent and purpose of the foregoing.

Agreements, commitments, documents, instruments and other writings executed by the Attorney in accordance with the terms hereof shall be binding upon the Company without attestation and without affixation of the seal of the Company. The Power of Attorney conferred hereby shall not be delegable by any Attorney. The Attorney shall serve without compensation for acting in the capacity of agent and attorney-in-fact hereunder.

The Company confirms that all acts done and documents executed or signed by any Attorney-in-Fact in the proper or purported exercise of any such Attorney-in-Fact's powers and/or authorities hereunder shall for all purposes be conclusive, valid, legally binding and enforceable on the Company, its successors and assigns, without countersignature, attestation and without affixation of the corporate seal of the Company.

The following provisions shall govern this power of attorney ("POA"):

1. This POA shall be effective as of the Effective Date and remain in effect as to any specific Attorney-in-Fact until the earlier of (i) two (2) years after the Effective Date, (ii) this POA being revoked in writing as to such Attorney-in-Fact, and (iii) such Attorney-in-Fact no longer being employed by the Company or one of its affiliates;
2. This POA shall be governed by and construed in accordance with the laws of the State of New York; and
3. This POA may be executed by electronic means and a signed copy of this POA delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same effect as an original.

IN WITNESS WHEREOF, the Company has caused the Power of Attorney to be executed as of the 22nd day of June 2018.

General Electric Company

By: /s/ Thomas Mitchell
Name: Thomas D. Mitchell
Title: VP, Sourcing

POWER OF ATTORNEY

Effective as of June 22, 2018 (the "Effective Date"), GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC., (the "Company"), a corporation organized and existing under and by virtue of the laws of the State of Wisconsin, United States of America, and having a principal place of business at 8200 W. Tower Avenue, Milwaukee, WI 53223, United States of America, hereby appoints and constitutes the following persons:

Name of Attorney:

Emmanuel Ligner	Stephen Kanovsky
Raul Grable	Derek Vander Heide

each individually as its true and lawful attorney-in-fact (each, an "Attorney-in-Fact"), hereby giving and granting him or her full power and authority in the name and on behalf of the Company to do the following:

Each Attorney shall have the power and authority to execute and deliver any Schedule 13D, Schedule 13G or Forms 3, 4 and 5 or any amendments thereto required to be filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934 on behalf of the Company with regard to any securities owned by the Company or any of its subsidiaries; and, in connection with the foregoing, to execute and deliver all documents, acknowledgments, consents and other agreements and to take such further action as may be necessary or convenient for the Company in order to more effectively carry out the intent and purpose of the foregoing.

Agreements, commitments, documents, instruments and other writings executed by the Attorney in accordance with the terms hereof shall be binding upon the Company without attestation and without affixation of the seal of the Company. The Power of Attorney conferred hereby shall not be delegable by any Attorney. The Attorney shall serve without compensation for acting in the capacity of agent and attorney-in-fact hereunder.

The Company confirms that all acts done and documents executed or signed by any Attorney-in-Fact in the proper or purported exercise of any such Attorney-in-Fact's powers and/or authorities hereunder shall for all purposes be conclusive, valid, legally binding and enforceable on the Company, its successors and assigns, without countersignature, attestation and without affixation of the corporate seal of the Company.

The following provisions shall govern this power of attorney ("POA"):

1. This POA shall be effective as of the Effective Date and remain in effect as to any specific Attorney-in-Fact until the earlier of (i) two (2) years after the Effective Date, (ii) this POA being revoked in writing as to such Attorney-in-Fact, and (iii) such Attorney-in-Fact no longer being employed by the Company or one of its affiliates;
2. This POA shall be governed by and construed in accordance with the laws of the State of New York; and
3. This POA may be executed by electronic means and a signed copy of this POA delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same effect as an original.

IN WITNESS WHEREOF, the Company has caused the Power of Attorney to be executed as of the 22nd day of June 2018.

GE MEDICAL SYSTEMS
INFORMATION
TECHNOLOGIES, INC.

By: /s/ Benjamin Clark
Name: Benjamin Clark
Title: President

